Reason for request
Inclusion on the list of medicines refundable by National Health Insurance and approved for hospital use.
Clinical Benefit
| Substantial |
The actual benefit of ZYTIGA is substantial. |
Clinical Added Value
| moderate |
ZYTIGA provides a moderate improvement in actual benefit (level III) in terms of efficacy and tolerance in the treatment of metastatic castration-resistant prostate cancer which progresses during or after docetaxel therapy. |
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
zLeWqhqcRAqSv3vQ
